Lv12
20 积分 2025-05-27 加入
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
1天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
13天前
已完结
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Apatinib mesylate in the treatment of advanced triple-negative breast cancer
2个月前
已完结
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
3个月前
已完结
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
3个月前
已完结
A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer
3个月前
已完结
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
3个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
4个月前
已完结
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
6个月前
已完结
皖公网安备34019202002308
